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High-density lipoprotein (HDL) and its principal apolipoprotein A-I (ApoA-I) have now
been convincingly shown to influence glucose metabolism through multiple mechanisms.
The key clinically relevant observations are that both acute HDL elevation via short-
term reconstituted HDL (rHDL) infusion and chronically raising HDL via a cholesteryl
ester transfer protein (CETP) inhibitor reduce blood glucose in individuals with type 2
diabetes mellitus (T2DM). HDL may mediate effects on glucose metabolism through
actions in multiple organs (e.g., pancreas, skeletal muscle, heart, adipose, liver, brain)
by three distinct mechanisms: (i) Insulin secretion from pancreatic beta cells, (ii) Insulin-
independent glucose uptake, (iii) Insulin sensitivity. The molecular mechanisms appear
to involve both direct HDL signaling actions as well as effects secondary to lipid
removal from cells. The implications of glucoregulatory mechanisms linked to HDL extend
from glycemic control to potential anti-ischemic actions via increased tissue glucose
uptake and utilization. Such effects not only have implications for the prevention and
management of diabetes, but also for ischemic vascular diseases including angina
pectoris, intermittent claudication, cerebral ischemia and even some forms of dementia.
This review will discuss the growing evidence for a role of HDL in glucose metabolism
and outline related potential for HDL therapies.
Keywords: HDL, glucose uptake, insulin sensitivity, insulin secretion, glucose metabolism, apolipoprotein A-I,
cholesterol efflux
INTRODUCTION
There is accumulating experimental and clinical evidence that HDL particles can control glucose
metabolism via a variety of mechanisms (Drew et al., 2012; von Eckardstein and Widmann, 2014).
At a mechanistic level HDL particles can alter multiple aspects of glucose metabolism. These include
insulin secretion from pancreatic beta cells, and both insulin-dependent and insulin-independent
glucose uptake andutilization in tissues. Someof these effects aremediated by direct signaling actions
of HDL and its components, whilst others appear to be secondary to other known HDL functions,
including tissue lipid efflux.
The action of HDL to move glucose from the circulation and into tissues has potential clinical
relevance in terms of both reducing vascular complications by removing excess glucose from the
Abbreviations: ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1; ABCG1 ATP-binding cassette, sub-
family G (ABC1), member 1; AMPK AMP-activated protein kinase; ApoA-I apolipoprotein A-I; ApoE apolipoprotein
E; CaMKK calcium/calmodulin activated protein kinase; CETP cholesteryl ester transfer protein; CNS central nervous
system; CSF cerebral spinal fluid; ER endoplasmic reticulum; GLUT4 glucose transporter 4; HDL high-density
lipoprotein; LDL low-density lipoprotein; rHDL reconstituted HDL; S1P sphingosine-1-phosphate; T2DM type 2
diabetes mellitus.
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circulation in the setting of T2DM, and also in providing
adequate glucose to tissues for energy production, particularly in
the context of ischemia. HDL therapeutics may therefore have
application not only for the prevention andmanagement of T2DM
(Drew et al., 2012; von Eckardstein and Widmann, 2014), but
also for ischemic vascular diseases including angina pectoris,
intermittent claudication, cerebrovascular disease (Kingwell and
Chapman, 2013) and even some forms of dementia (Stukas et al.,
2014b).
This review will discuss the growing evidence for a role of
HDL in glucose metabolism in the context of the evolving HDL
hypothesis. It is now recognized that the main clinical variable
used to assess HDL, HDL cholesterol, fails to provide an accurate
representation of the multiple functions of heterogeneous HDL
particles, which are composed of many hundreds of lipids and
multiple proteins (Khera et al., 2011; Kingwell et al., 2014; Rohatgi
et al., 2014; Saleheen et al., 2015). The role of HDL in glucose
metabolism will be explored from the perspective of both disease
pathophysiology and the potential for HDL therapies targeting
this mechanism.
HDL, GLUCOSE METABOLISM, AND T2DM
T2DM, insulin resistance and glucose intolerance are associated
with low HDL cholesterol levels (Ford et al., 2002; Drexel et al.,
2005; Gatti et al., 2009). While there are clear mechanisms by
which insulin resistance contributes to lowHDL cholesterol, there
is also evidence that low HDLmay actually promote development
of diabetes (Drew et al., 2012). Low HDL cholesterol levels
predict development of T2DM in prediabetics (Haffner et al.,
1990) and progression of glycemia in those with established
T2DM (Waldman et al., 2014). With the recent recognition of
the importance of HDL function above simple plasma HDL
cholesterol concentration (Rohatgi et al., 2014), it is interesting
to note that HDL cholesterol efflux capacity is inversely related to
T2DM in the EPIC Norfolk study (Saleheen et al., 2015).
On the other hand, a recent Mendelian randomization study
showed that genetically reduced HDL cholesterol does not
associate with increased risk of T2DM (Haase et al., 2015).
While this may reflect that the observational association is due
to confounding and/or reverse causation, consideration must
also be given to the fact that HDL cholesterol, while clinically
accessible, does not accurately reflect HDL function and may
not therefore be the best instrumental variable to test. As HDL
function assays such as cholesterol efflux capacity become feasible
in larger data sets, the hypothesis that HDL function may
contribute causally to the risk of T2DM can be further explored
using Mendelian approaches. In the meantime, mechanistic
and intervention studies are uncovering links between HDL
and glucose metabolism, which may have physiological and
therapeutic relevance.
Insulin Secretion
High-density lipoprotein has been implicated in the modulation
of insulin secretion in cellular and animal studies with
corroborating evidence from human intervention trials.
The diverse functionality of HDL to combat cellular lipid
accumulation, endoplasmic reticulum (ER) stress and apoptosis
are three potential mechanisms that may preserve pancreatic beta
cell function.
Pancreatic lipid accumulation and lipotoxicity have been well-
documented to inhibit insulin production and secretion (Hao
et al., 2007). We have shown that impairment of glucose-
stimulated insulin secretion induced by oxidized low-density
lipoprotein (LDL) can be countered by native HDL (50mg/mL)
treatment (Drew et al., 2009). Further to this, a single dose of
either wild-type ApoA-I (major protein component of HDL) or
ApoA-I Milano was able to potentiate glucose-stimulated insulin
secretion in high-fat fed mice (Stenkula et al., 2014). These effects
on beta cell function may be mediated by the bioactive lipid
sphingosine-1-phosphate (S1P), which is primarily carried within
HDL particles and is known to independently promote glucose-
stimulated insulin secretion (Cantrell Stanford et al., 2012).
At the signaling level the HDL transporters ATP-binding
cassette, sub-family A, member 1 (ABCA1) and ATP-binding
cassette, sub-family G, member 1 (ABCG1) have both been
implicated in HDL-mediated effects on insulin secretion. Beta
cell-specific deletion of the ABCA1 (Brunham et al., 2007)
and ABCG1 (Sturek et al., 2010) transporters in mice impairs
both cholesterol homeostasis and insulin secretion. Combined
inactivation of ABCA1 and ABCG1 in beta cells increased
intracellular cholesterol accumulation and induced beta cell
inflammation, exacerbating the insulin secretory defect found
in the single transporter knockout mice (Kruit et al., 2012).
Furthermore, post-transcriptional suppression of ABCA1 via
over expression of miR33a and miR145 in beta cells increased
islet cholesterol levels and decreased glucose-stimulated insulin
secretion (Wijesekara et al., 2012; Kang et al., 2013); effects that
could be rescued by cholesterol depletion.
HDL may also influence insulin secretion via mechanisms
other than cholesterol depletion, including via actions on insulin
transcription (Fryirs et al., 2009; Cochran et al., 2014). At doses
of up to 900mg/mL, lipid-free recombinant ApoA-I, ApoA-II and
discoidal rHDL dose-dependently increased basal and glucose-
stimulated insulin secretion in addition to insulin transcription
(Fryirs et al., 2009). Whereas other experiments in MIN6 cells,
as well as in islets isolated from mice and humans, found no
evidence that HDL can directly enhance insulin production, basal
or glucose-stimulated insulin secretion (Abderrahmani et al.,
2007; Rutti et al., 2009).
The ability of HDL to inhibit ER stress-induced beta cell
apoptosis could be another important mechanism by which HDL
may ameliorate beta cell dysfunction (Petremand et al., 2009; Rutti
et al., 2009). Bioactive lipids associated with HDL, such as S1P
may also mediate anti-apoptotic effects on beta cells indirectly by
interfering with the release of proapoptotic signals from non beta-
cells within the pancreatic islet (Vollenweider et al., 2015). While
it is more challenging to directly examine the effects of HDL on
insulin secretion in humans, acute infusion of rHDL in patients
with T2DM increased plasma insulin concentrations (Drew et al.,
2009). Chronic HDL elevation induced by a CETP inhibitor
in healthy individuals was also associated with an increase
in postprandial plasma insulin and C-peptide concentrations
(Siebel et al., 2013). Furthermore, plasma taken from these CETP
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FIGURE 1 | Schematic diagram of the pathways activated by HDL in skeletal muscle that modulate glucose metabolism. Both human and rodent studies
have demonstrated that HDL can increase glucose uptake through an ABCA1/AMPK-dependent mechanism (Drew et al., 2009). Chronically elevating HDL levels
pharmacologically or via genetic approaches in mice increases Akt phosphorylation, suggesting activation of an additional signaling pathway (Lehti et al., 2013).
There is also more recent evidence in mouse muscle cells showing that HDL can directly stimulate anaerobic glycolysis and glucose oxidation.
inhibitor-treated individuals increased glucose-stimulated insulin
secretion and cholesterol efflux from MIN6 beta cells relative to
plasma from placebo-treated individuals. In this study, the actions
of CETP inhibition on glucose-stimulated, but not basal insulin
secretion suggests that HDL may be important in minimizing
postprandial glucose excursions without raising resting insulin
levels. Future clinical studies utilizing stable isotope tracers and
minimal modeling techniques (Cobelli et al., 2014) are warranted
to more directly characterize the effects of HDL on postprandial
insulin secretion and glucose metabolism.
Insulin-independent Glucose Uptake
in Skeletal Muscle
We have previously shown that acute rHDL infusion can reduce
blood glucose in individuals with T2DM (Drew et al., 2009).
This reduction in glucose preceded an increase in plasma insulin,
supporting the hypothesis that HDL may also mediate insulin-
independent glucose uptake within skeletal muscle (Drew et al.,
2009). This has been further investigated in primary human
skeletal muscle cells and adipocytes where both HDL and ApoA-I
promoted glucose uptake independently of insulin stimulation
(Han et al., 2007; Drew et al., 2009; Zhang et al., 2011; Dalla-Riva
et al., 2013). Figure 1 depicts the intracellular signaling pathways
activated by HDL in skeletal muscle. HDL-associated ApoA-I
binds to ABCA1 inducing intracellular Ca2+ influx and activation
of calcium/calmodulin activated protein kinase kinase (CaMKK)
(Drew et al., 2009). Subsequent activation and phosphorylation of
AMP-activated protein kinase (AMPK) increases translocation of
glucose transporter 4 (GLUT4) to the plasma membrane (Dalla-
Riva et al., 2013) and facilitates glucose uptake.
Beyond glucose uptake, HDL has been shown to activate Akt in
ApoA-I transgenic mice and directly enhance both glycolysis and
glucose oxidation inmouseC2C12muscle cells (Lehti et al., 2013).
These insulin-independent effects ofHDLon glucosemetabolism,
may actually account, at least partly, for in vivo effects of HDL on
glucose disposal in the absence of a change in circulating insulin.
Such effects may be mistakenly attributed to increased insulin
sensitivity.
Insulin Sensitivity and Glucose
Homeostasis
Tissue lipid deposition and chronic inflammation associated
with obesity, metabolic syndrome and T2DM establishes a
functional deficit in skeletal muscle and the heart, impairing
how these metabolically active tissues respond to insulin. The
insulin resistance associated with lipid accumulation and a pro-
inflammatory milieu promotes lipolysis, increasing circulating
free fatty acids, thus perpetuating dyslipidemia and insulin
resistance (Hotamisligil, 2006; Klop et al., 2013). It is still unclear
whether it is the persistent hyperglycemia associated with T2DM
that leads to the chronic inflammation typical of metabolic
syndrome or whether the inflammatory response triggers an
imbalance in glucose control and leads to insulin resistance. Either
way via its effects on reverse cholesterol transport, functional
HDL can remove lipids from peripheral cells and potentially
ameliorate inflammation (Reviewed, in Navab et al., 2011). There
is some cellular evidence that HDL elevation can increase insulin
sensitivity in peripheral tissues (Carey et al., 2013).
Examining insulin sensitivity in vivo is more complex due to
the fact that increased glucose disposal relative to insulin may not
necessarily reflect increased insulin sensitivity. As discussed in the
previous section, such observations may actually be explained by
direct actions of HDL on glucose disposal by mechanisms which
do not involve insulin. Nevertheless, there are two recent in vivo
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studies consistent with the cellular studies, which suggest that
HDL/ApoA-I can increase peripheral insulin sensitivity. The first
of these employed intraperitoneal glucose and insulin tolerance
tests in high fat diet fed mice treated for 2–4 weeks with lipid-free
ApoA-I (8mg/kg body weight) and showed improved glucose and
insulin tolerance compared to untreatedmice on the same high fat
diet (McGrath et al., 2014). The second raised HDL cholesterol
levels using the CETP inhibitor torcetrapib in insulin resistant
hamsters and found that torcetrapib increased insulin-stimulated
glucose uptake in skeletal muscle, liver and the heart, improving
glucose homeostasis (Briand et al., 2014).
There are a number of animal studies that implicate HDL
and/or ApoA-I in the maintenance of glucose homeostasis, with
considerable conjecture over whether HDL has a direct effect on
insulin sensitivity. The relevance of these findings is generally
not clear due to a lack of insulin tolerance (or more accurately
insulin responsiveness) testing or hyperinsulinemic-euglycemic
clamp studies to examine direct effects on insulin sensitivity.
Definitive evidence for an effect of HDL on insulin sensitivity in
humans is also lacking. However, HDL cholesterol elevation by
CETP inhibition has been shown to improve glycemic control in
the face of reduced plasma insulin in people with T2DM in the
ILLUMINATE trial (Barter et al., 2011). As evidence for a role of
HDL in glucose metabolism accumulates, clinical trials of HDL
therapies are now including glycemic endpoints to further test
clinical relevance.
NEW DIRECTIONS FOR HDL
AND GLUCOSE METABOLISM
The actions of HDL on glucose metabolism have potential
benefit beyond vascular protection. The ability of HDL to
stimulate tissue glucose uptake has implications for cellular
metabolism in the brain, as well as for cell viability in other
organs under ischemic/anoxic conditions where glucose becomes
the predominant metabolic substrate. This latter mechanism
may have particular relevance to ischemic vascular conditions,
including coronary, cerebral and peripheral artery diseases.
Ischemic Heart Disease
We have recently established that HDL increases insulin-
independent glucose uptake in rat cardiomyocytes via an Akt
signaling pathway (Heywood et al., 2014). In this cardiomyocyte
model, the AMPK pathway involved in human skeletal muscle
cell glucose uptake is not activated by HDL. It is known that
plasma levels of HDL cholesterol are strongly associated with
increased glucose disposal during the acute phase of myocardial
infarction (Carvalho et al., 2012, 2013). However, the relevance of
HDL-mediated glucose uptake tomyocardial protection in human
ischemic heart disease has not been established.
Insulin resistance may directly contribute to the increased risk
of ischemic heart disease and poorer outcomes after infarction
in patients with T2DM (Icks et al., 2014). It is plausible that
HDLmay improve cardiac function by directly increasing glucose
uptake in addition to promoting efficient coupling of anaerobic
glycolysis to glucose oxidation in the heart. This is particularly
relevant in the setting of acute coronary syndromes where the
ischemic myocardium is exposed to an acute ATP deficit, which
can be ameliorated by targeting glucose metabolism immediately
post-event in mice (Ussher et al., 2012; Masoud et al., 2014).
In addition, the well-established vasodilatory effects of HDL via
nitric oxide production (Mineo et al., 2003; Drew et al., 2004) may
also enhance glucose uptake via microcirculatory vasodilatation
allowing insulin and glucose access to nutritive vascular beds.
The emerging actions of HDL and its bioactive components
on glucose metabolism in the myocardium may contribute to
the demonstrated protective effects of HDL in the context of
ischemia-reperfusion injury (Calabresi et al., 2003; Theilmeier
et al., 2006; Herzog et al., 2010; Tao et al., 2010; Brulhart-
Meynet et al., 2015). Such actions may be particularly important
in the setting of T2DM, where non-insulin mediated glucose
uptake could support tissue viability in the face of insulin
resistance. Further investigations are required to determine
the relevance of HDL-mediated effects on glucose metabolism
and their relevance under ischemic conditions both in the
presence and absence of insulin resistance. In this regard, novel
reconstituted and recombinant HDLs have particular potential as
anti-ischemic therapeutics in the setting of both acute coronary
syndromes and coronary surgeries involving bypass procedures
including coronary artery grafts (Kingwell and Chapman, 2013).
Current trials with HDL infusion therapies (NCT02108262 and
NCT02484378) will provide further insights into the actions of
HDL in the context of acute coronary syndromes, though the
potential role of glucose metabolism will not be discernible.
Cerebrovascular Disease
For the same reasons that HDL-mediated effects on glucose
metabolism may protect the ischemic myocardium, these actions
may equally act in the brain to protect against transient ischemic
attacks and stroke. In fact, the reliance of the brain on glucose
for ATP production means that mechanisms controlling glucose
uptake may be of even greater significance than in other organs.
Even minor changes in cerebral blood flow have the potential
to impact on neuronal viability via reduction in glucose supply.
Indeed cerebral hypoperfusion and hypometabolism coincide in
patients with dementia (Verfaillie et al., 2015).
The implications of reduced blood flow, and thus glucose
supply to the brain, extend beyond acute stroke risk to Alzheimer’s
disease, which has a significant vascular component (Di Marco
et al., 2015). In this condition, cerebral blood flow is reduced
by 10–30% in many brain regions, including those responsible
for cognitive function and memory, with the extent of blood
flow impairment correlating with disease severity (Jagust et al.,
1997; Johnson et al., 1998; Hanyu et al., 2010; Kim et al., 2013).
This reduction in cerebral blood flow is also detected prior
to cognitive decline or amyloid accumulation. However, most
relevant to this review, glucose uptake and utilization in the brain
is also reduced in Alzheimer’s disease, mild cognitive impairment
patients and transgenic animal models of Alzheimer’s disease
(Herholz, 2010; Jagust et al., 2010; Shin et al., 2010; Nicolakakis
and Hamel, 2011). Whether HDL can increase cerebral blood
flow and glucose uptake in the central nervous system (CNS) is
not currently known, but certainly worth exploring. Evidence
to date has shown beneficial associations between brain
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health and HDL, but the contributing mechanisms have not been
fully elucidated.
Given the well-established positive actions of HDL on vascular
function, it is not surprising that several co-morbidities associated
with increased Alzheimer’s disease risk are themselves associated
with decreased HDL function (Riwanto and Landmesser, 2013).
A role for HDL in glucose handling in the brain is an interesting
candidate to partly explain the association of reduced circulating
levels of HDL/ApoA-I with Alzheimer’s disease (Kuriyama et al.,
1994; Kawano et al., 1995; Merched et al., 2000; Castano et al.,
2006; Roher et al., 2009). Othermechanismsmay relate to removal
or breakdown of b-amyloid or reduction in its cytotoxicity
(Paula-Lima et al., 2009; Lefterov et al., 2010). In this respect,
ApoA-I may have actions analogous to apolipoprotein E (ApoE)
where common genetic variants have directly opposing effects
on b-amyloid deposition and clearance and therefore risk for
Alzheimer’s disease (Corder et al., 1993). ApoE is the major
apolipoprotein synthesized by astrocytes and microglia in the
brain and forms lipoprotein particles that resembleHDLs found in
plasma. Similarly to ApoA-I, ApoE is lipidated by ABCA1 (Pitas
et al., 1987; LaDu et al., 1998; Fagan et al., 1999). Further work
is required to understand the role of HDL and ApoA-I in brain
lipid and glucose metabolism, both in the cerebral vasculature
as well as neurons and glial cells and how this might relate to
pathophysiology.
One important consideration for the potential application of
HDL therapeutics to brain disorders is whether they can cross
the blood-brain or blood-cerebral spinal fluid (CSF) barrier
(Zlokovic, 2011). ApoA-I has been previously found in the CSF
at relatively high levels (0.07–4 mg/mL or 0.1–0.5% plasma
levels), (Koch et al., 2001) which is encouraging given the
in vitro efficacy of ApoA-I at similar concentrations. More
recently, Stukas et al. (2014a) have shown that intravenous
injection of recombinant human ApoA-I specifically localizes to
the choroid plexus. These data, along with in vitro primary cell
culture experiments, suggest that plasma ApoA-I gains access
to the CNS primarily by crossing the blood-CSF barrier via
specific cellular mediated transport (Stukas et al., 2014a). The
blood-CSF barrier is made up of highly fenestrated cuboidal
epithelial cells within the choroid plexus (Lehtinen et al.,
2013), which may explain how ApoA-I enters the CSF from
the blood. This suggests that aside from the vasodilatory,
anti-inflammatory and anti-oxidative actions of HDL/ApoA-I
that could target cerebrovascular complications in Alzheimer’s
disease, targeting brain-specific glucose metabolism may also be
possible.
CONCLUSION
There is now convincing evidence that HDL modulates glucose
metabolism in multiple tissues. These actions have deepened
our understanding of the pathophysiology of a variety of
disease states associated with low or dysfunctional HDL. While
there are still many unanswered questions relating to the
underlying mechanisms and key HDL component(s) responsible
for the metabolic effects, this opens up the possibility of
targeting glucose metabolism with HDL therapeutics currently in
development. Future preclinical investigations and clinical trials
will determine the relevance of HDL-mediated modulation of
glucose metabolism to both glycemic control as well as tissue
glucose supply to vital organs including the heart and the brain,
especially under ischemic conditions.
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